Glenmark Pharmaceuticals Inc., USA, has announced the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This product is expected to deliver the same therapeutic benefits as Acetadote® Injection by Cumberland Pharmaceuticals Inc.
Glenmark acquired the ANDA (Abbreviated New Drug Application) for Acetylcysteine Injection from Aspen Pharma USA Inc. The injection is used in hospitals for treating acetaminophen overdoses and other medical conditions requiring detoxification support.
According to IQVIA™ sales data, the market for Acetadote® Injection reached approximately $15.2 million in annual sales as of January 2025. Glenmark’s latest launch strengthens its injectable portfolio in the U.S. market, catering to the hospital segment.
Marc Kikuchi, President & Business Head, North America, stated, “We are excited to announce the acquisition and launch of Acetylcysteine Injection, 6 gm/30 mL (200 mg/mL) Single-Dose Vials. This is a great addition to our injectable portfolio in the U.S. market as we continue to drive growth for the hospital segment.”
